ADARx Pharmaceuticals Seeks $1.74 Billion IPO Valuation for RNA Therapies

By EC Assets · Published 21 September 2026

ADARx Pharmaceuticals, a clinical stage biotechnology company, aims for a $1.74 billion valuation in its upcoming U.S. initial public offering. The company filed for a U.S. IPO to secure funding for its RNA therapy pipeline. ADARx Pharmaceuticals develops next-generation RNA therapeutics. The company seeks to fund ongoing clinical trials for a range of next-generation small interfering RNA (siRNA) medicines. Its IPO specifically aims to fund its RNA therapy pipeline. ADARx Pharmaceuticals' pipeline includes drugs designed to regulate gene expression to treat various diseases. AbbVie is a significant backer of ADARx Pharmaceuticals. The biotech firm has reinvigorated its ambitions to go public with AbbVie's support. A collaboration and license option agreement exists between AbbVie and ADARx Pharmaceuticals. This agreement focuses on developing next-generation siRNA therapies across multiple therapeutic areas. The collaboration leverages AbbVie's expertise in biotherapeutic drug development and commercialization. It also utilizes ADARx's proprietary RNA technology to advance siRNA therapies. ADARx Pharmaceuticals is a late-stage biotechnology company as of February 2026. The company appointed Dr. Chris Storgard as Chief Medical Officer in April 2024. Donald Fong, M.D. was appointed Chief Medical Officer in February 2026. ADARx Pharmaceuticals' IPO seeks to fund its RNA therapy pipeline and provides validation through its collaboration deal with AbbVie. The company develops next-generation RNA therapeutics. Its pipeline includes Phase 3 Onvuzosiran, a timeline for which is available. The company's goal is to advance its array of clinical-stage siRNA therapies. This article is intended for informational purposes only. It does not constitute investment advice.